Siemens Healthineers now offers the Anti-Müllerian Hormone (AMH) Assay to quickly evaluate ovarian reserve. The AMH Assay is an important addition to a laboratory's reproductive endocrinology test menu as it aids a physician's initial assessment about initiating in vitro fertilization (IVF) with a patient. Physicians use AMH test results, which indicate the volume of remaining eggs, to determine whether a patient's ovaries may respond favorably to IVF.
IVF is the most common form of assisted reproductive technology, and it is costly, time-consuming, and invasive. In an ideal scenario, IVF is the process by which the ovaries are stimulated through a series of hormonal injections to release eggs that are then removed from the body via a transvaginal procedure, fertilized in a petri dish using a partner or donor sperm, and then returned as an embryo to develop into pregnancy in the uterus. The average patient goes through two IVF cycles that take several weeks. In the United States, the cost of IVF treatment is not always covered by insurance and the average patient undergoes two IVF cycles costing roughly $40,000-$60,000.1
"Planning for pregnancy is very personal, and when planning for pregnancy does become top-of-mind, the reality is that naturally occurring fertility changes can create barriers to conception and require support through IVF,” said Sharon Bracken, head of Diagnostics, Siemens Healthineers. “Since IVF success is directly linked to ovarian reserve, AMH test results can help doctors empower patients as they work toward the complex decision about whether to pursue or continue IVF."
The insight the AMH Assay from Siemens Healthineers provides can help doctors better understand a patient's ovarian reserve and assist in consulting patients about whether to undergo IVF with a view to likelihood of success. Once in treatment, data gained from AMH testing can help reduce the number of IVF attempts, which can reduce financial cost as well as minimize adverse reactions associated with treatment.
About Siemens Healthineers Women's Health Offerings
Siemens Healthineers provides assays and systems to meet the needs of patients throughout their lives. By offering a broad reproductive endocrinology test menu, laboratories can better serve IVF patients eager for answers as quickly as possible, and support physicians with results that help inform their development of the clinical service they deliver. Learn about the Siemens Healthineers Reproductive Endocrinology test menu here. Beyond laboratory tests, Siemens Healthineers offers an extensive portfolio for women's health, including ultrasound technology, mammography systems, magnetic resonance scanners and other imaging solutions to support cancer care.
Media Contact
Kimberly Nissen
Phone: +1 610-241-2129
Email: Kimberly.Nissen@siemens-healthineers.com
Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2023, which ended on September 30, 2023, Siemens Healthineers had approximately 71,000 employees worldwide and generated revenue of around €21.7 billion. Further information is available at www.siemens-healthineers.com.
Proposed Tweet:
Pregnancy through in vitro fertilization is costly, time-consuming, and invasive. New reproductive assay from Siemens Healthineers provides critical information to inform IVF decisions [insert link to press release]
